Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
All content curated by
Published in Oncology

Journal Scan / Research · January 22, 2023

Upfront Autologous HSCT vs Carfilzomib–Cyclophosphamide–Dexamethasone Consolidation With Carfilzomib Maintenance for Newly Diagnosed Multiple Myeloma

The Lancet Haematology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Haematology
Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial
Lancet Haematol 2022 Dec 15;[EPub Ahead of Print], K Yong, W Wilson, RM de Tute, M Camilleri, K Ramasamy, M Streetly, J Sive, CA Bygrave, R Benjamin, M Chapman, SJ Chavda, EH Phillips, M Del Mar Cuadrado, G Pang, R Jenner, T Dadaga, S Kamora, J Cavenagh, L Clifton-Hadley, RG Owen, R Popat

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading